Oncolytics Biotech Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study
| ONCY Stock | USD 0.91 0.02 2.15% |
Slightly above 62% of Oncolytics Biotech's investor base is looking to short. The analysis of the overall investor sentiment regarding Oncolytics Biotech suggests that many traders are alarmed. Oncolytics Biotech's investing sentiment can be driven by a variety of factors including economic data, Oncolytics Biotech's earnings reports, geopolitical events, and overall market trends.
Oncolytics |
Oncolytics Biotech Inc. , a leading clinical-stage company specializing in immunotherapy for oncology, today announced positive clinical results from BRACELET-1, its randomized Phase 2 study evaluating pelareorep in patients with HRHER2- advanced or metastatic breast cancer.
Read at finance.yahoo.com
 |
Oncolytics Biotech Fundamental Analysis
We analyze Oncolytics Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oncolytics Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oncolytics Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Institutions
Shares Owned By Institutions Comparative Analysis
Oncolytics Biotech is currently under evaluation in shares owned by institutions category among its peers. Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Oncolytics Biotech Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Oncolytics Biotech stock to make a market-neutral strategy. Peer analysis of Oncolytics Biotech could also be used in its relative valuation, which is a method of valuing Oncolytics Biotech by comparing valuation metrics with similar companies.
Peers
Oncolytics Biotech Related Equities
| DMAC | DiaMedica Therapeutics | 5.71 | ||||
| CVAC | CureVac NV | 5.41 | ||||
| HOOK | Hookipa Pharma | 2.72 | ||||
| KRYS | Krystal Biotech | 2.53 | ||||
| DAWN | Day One | 1.64 | ||||
| IKT | Inhibikase Therapeutics | 1.58 | ||||
| MIST | Milestone Pharmaceuticals | 1.37 | ||||
| VIR | Vir Biotechnology | 0.75 | ||||
| TERN | Terns Pharmaceuticals | 1.40 | ||||
| SCPH | Scpharmaceuticals | 1.66 | ||||
| MCRB | Seres Therapeutics | 4.40 | ||||
| XFOR | X4 Pharmaceuticals | 5.41 |
Additional Tools for Oncolytics Stock Analysis
When running Oncolytics Biotech's price analysis, check to measure Oncolytics Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncolytics Biotech is operating at the current time. Most of Oncolytics Biotech's value examination focuses on studying past and present price action to predict the probability of Oncolytics Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncolytics Biotech's price. Additionally, you may evaluate how the addition of Oncolytics Biotech to your portfolios can decrease your overall portfolio volatility.